

Andrea Wittig

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11440782/publications.pdf>

Version: 2024-02-01

60
papers

1,985
citations

279798

23
h-index

254184

43
g-index

61
all docs

61
docs citations

61
times ranked

2513
citing authors

#	ARTICLE	IF	CITATIONS
1	Stereotactic body radiotherapy of adrenal metastasesâ€”A doseâ€¢finding study. <i>International Journal of Cancer</i> , 2022, 151, 412-421.	5.1	4
2	Early Mortality among Patients with Head and Neck Cancer Diagnosed in Thuringia, Germany, between 1996 and 2016â€”A Population-Based Study. <i>Cancers</i> , 2022, 14, 3099.	3.7	3
3	Role of Intraparotid and Neck Lymph Node Metastasis in Primary Parotid Cancer Surgery: A Population-Based Analysis. <i>Cancers</i> , 2022, 14, 2822.	3.7	7
4	Stereotactic or conformal radiotherapy for adrenal metastases: Patient characteristics and outcomes in a multicenter analysis. <i>International Journal of Cancer</i> , 2021, 149, 358-370.	5.1	24
5	Influence of adjuvant radiotherapy on circulating epithelial tumor cells and circulating cancer stem cells in primary non-metastatic breast cancer. <i>Translational Oncology</i> , 2021, 14, 101009.	3.7	9
6	Theranostics in Boron Neutron Capture Therapy. <i>Life</i> , 2021, 11, 330.	2.4	32
7	Longâ€¢Term Facial Nerve Outcome in Primary Parotid Cancer Surgery: A Populationâ€¢Based Analysis. <i>Laryngoscope</i> , 2021, 131, 2694-2700.	2.0	6
8	Prospective Monitoring of Circulating Epithelial Tumor Cells (CETC) Reveals Changes in Gene Expression during Adjuvant Radiotherapy of Breast Cancer Patients. <i>Current Oncology</i> , 2021, 28, 3507-3524.	2.2	2
9	Gender Disparities in Epidemiology, Treatment, and Outcome for Head and Neck Cancer in Germany: A Population-Based Long-Term Analysis from 1996 to 2016 of the Thuringian Cancer Registry. <i>Cancers</i> , 2020, 12, 3418.	3.7	27
10	HPV-positive HNSCC cell lines show strongly enhanced radiosensitivity after photon but not after carbon ion irradiation. <i>Radiotherapy and Oncology</i> , 2020, 151, 134-140.	0.6	6
11	Dual PI3K/mTOR Inhibitor NVP-BEZ235 Enhances Radiosensitivity of Head and Neck Squamous Cell Carcinoma (HNSCC) Cell Lines Due to Suppressed Double-Strand Break (DSB) Repair by Non-Homologous End Joining. <i>Cancers</i> , 2020, 12, 467.	3.7	33
12	Long-term Follow-up and Patterns of Recurrence of Patients With Oligometastatic NSCLC Treated With Pulmonary SBRT. <i>Clinical Lung Cancer</i> , 2019, 20, e667-e677.	2.6	33
13	HPVâ€¢negative and HPVâ€¢positive HNSCC cell lines show similar numerical but different structural chromosomal aberrations. <i>Head and Neck</i> , 2019, 41, 3869-3879.	2.0	6
14	Urinary Proteomics Profiles Are Useful for Detection of Cancer Biomarkers and Changes Induced by Therapeutic Procedures. <i>Molecules</i> , 2019, 24, 794.	3.8	25
15	In HPV-Positive HNSCC Cells, Functional Restoration of the p53/p21 Pathway by Proteasome Inhibitor Bortezomib Does Not Affect Radio- or Chemosensitivity. <i>Translational Oncology</i> , 2019, 12, 417-425.	3.7	9
16	Monte Carlo Simulation of the Treatment of Uveal Melanoma Using Measured Heterogeneous 106Ru Plaques. <i>Ocular Oncology and Pathology</i> , 2019, 5, 276-283.	1.0	3
17	Validation of new 2D ripple filters in proton treatments of spherical geometries and non-small cell lung carcinoma cases. <i>Physics in Medicine and Biology</i> , 2018, 63, 245020.	3.0	6
18	Contemporary Management of Benign and Malignant Parotid Tumors. <i>Frontiers in Surgery</i> , 2018, 5, 39.	1.4	83

#	ARTICLE	IF	CITATIONS
19	Influence of Institutional Experience and Technological Advances on Outcome of Stereotactic Body Radiation Therapy for Oligometastatic Lung Disease. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 511-520.	0.8	42
20	Stereotactic body radiotherapy (SBRT) for pulmonary metastases from renal cell carcinoma—a multicenter analysis of the German working group “Stereotactic Radiotherapy”. <i>Journal of Thoracic Disease</i> , 2017, 9, 4512-4522.	1.4	43
21	Roscovitine strongly enhances the effect of olaparib on radiosensitivity for HPV neg. but not for HPV pos. HNSCC cell lines. <i>Oncotarget</i> , 2017, 8, 105170-105183.	1.8	17
22	Dosimetric comparisons of carbon ion treatment plans for 1D and 2D ripple filters with variable thicknesses. <i>Physics in Medicine and Biology</i> , 2016, 61, 4327-4341.	3.0	9
23	Stereotactic body radiotherapy (SBRT) for medically inoperable lung metastases—A pooled analysis of the German working group “stereotactic radiotherapy”. <i>Lung Cancer</i> , 2016, 97, 51-58.	2.0	128
24	Challenges in radiobiological modeling: can we decide between LQ and LQ-L models based on reviewed clinical NSCLC treatment outcome data?. <i>Radiation Oncology</i> , 2016, 11, 67.	2.7	34
25	Bayesian Cure Rate Modeling of Local Tumor Control: Evaluation in Stereotactic Body Radiation Therapy for Pulmonary Metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 841-849.	0.8	19
26	Local tumor control probability modeling of primary and secondary lung tumors in stereotactic body radiotherapy. <i>Radiotherapy and Oncology</i> , 2016, 118, 485-491.	0.6	101
27	Safety and Efficacy of Botulinum Toxin to Preserve Gland Function after Radiotherapy in Patients with Head and Neck Cancer: A Prospective, Randomized, Placebo-Controlled, Double-Blinded Phase I Clinical Trial. <i>PLoS ONE</i> , 2016, 11, e0151316.	2.5	20
28	Stereotactic body radiotherapy for centrally located stage I NSCLC. <i>Strahlentherapie Und Onkologie</i> , 2015, 191, 125-132.	2.0	52
29	Changes in the radiological depth correlate with dosimetric deterioration in particle therapy for stage I NSCLC patients under high frequency jet ventilation. <i>Acta Oncologica</i> , 2015, 54, 1631-1637.	1.8	6
30	Increased sensitivity of HPV-positive head and neck cancer cell lines to x-irradiation ± Cisplatin due to decreased expression of E6 and E7 oncoproteins and enhanced apoptosis. <i>American Journal of Cancer Research</i> , 2015, 5, 1017-31.	1.4	29
31	Increased radiosensitivity of HPV-positive head and neck cancer cell lines due to cell cycle dysregulation and induction of apoptosis. <i>Strahlentherapie Und Onkologie</i> , 2014, 190, 839-846.	2.0	98
32	Stereotactic radiosurgery for treatment of brain metastases. <i>Strahlentherapie Und Onkologie</i> , 2014, 190, 521-532.	2.0	179
33	Glioblastoma, brain metastases and soft tissue sarcoma of extremities: Candidate tumors for BNCT. <i>Applied Radiation and Isotopes</i> , 2014, 88, 46-49.	1.5	8
34	Support Vector Machine-Based Prediction of Local Tumor Control After Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 732-738.	0.8	54
35	Dosimetric consequences of intrafraction prostate motion in scanned ion beam radiotherapy. <i>Radiotherapy and Oncology</i> , 2014, 112, 100-105.	0.6	8
36	Quality of life after stereotactic radiotherapy for meningioma: a prospective non-randomized study. <i>Journal of Neuro-Oncology</i> , 2013, 113, 135-141.	2.9	24

#	ARTICLE	IF	CITATIONS
37	Reproducibility of target coverage in stereotactic spot scanning proton lung irradiation under high frequency jet ventilation. <i>Radiotherapy and Oncology</i> , 2013, 109, 45-50.	0.6	14
38	Dosimetric impact of reduced nozzle-to-isocenter distance in intensity-modulated proton therapy of intracranial tumors in combined proton-carbon fixed-nozzle treatment facilities. <i>Radiation Oncology</i> , 2013, 8, 218.	2.7	11
39	Applicability of the linear-quadratic formalism for modeling local tumor control probability in high dose per fraction stereotactic body radiotherapy for early stage non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2013, 109, 13-20.	0.6	103
40	Safety and Efficacy of Stereotactic Body Radiotherapy for Stage I Non-Small-Cell Lung Cancer in Routine Clinical Practice: A Patterns-of-Care and Outcome Analysis. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1050-1058.	1.1	179
41	Electron Irradiation of Conjunctival Lymphoma—Monte Carlo Simulation of the Minute Dose Distribution and Technique Optimization. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, 1330-1337.	0.8	15
42	Robustness Against Interfraction Prostate Movement in Scanned Ion Beam Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, e257-e262.	0.8	10
43	Drugs for BNCT: BSH and BPA. , 2012, , 117-160.		10
44	Boron Analysis and Boron Imaging in BNCT. , 2012, , 163-188.		0
45	Clinical Trials in BNCT: A Challenging Task. , 2012, , 369-376.		1
46	BPA uptake does not correlate with LAT1 and Ki67 expressions in tumor samples (results of EORTC trial) Tj ETQq0 0 0 rgBT /Q5verlock 10	1.5	5
47	Sodium mercaptoundecahydro-closo-dodecaborate (BSH), a boron carrier that merits more attention. <i>Applied Radiation and Isotopes</i> , 2011, 69, 1760-1764.	1.5	18
48	Metabolism of borono-phenylalanine-fructose complex (BPA-fr) and borocaptate sodium (BSH) in cancer patients—Results from EORTC trial 11001. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2010, 51, 284-287.	2.8	19
49	Hyperfractionated Accelerated Radiotherapy versus Conventional Fractionation Both Combined with Chemotherapy in Patients with Locally Advanced Head and Neck Carcinomas. <i>Oncology</i> , 2009, 76, 405-412.	1.9	6
50	EORTC trial 11001: distribution of two ¹⁰ B compounds in patients with squamous cell carcinoma of head and neck, a translational research/phase 1 trial. <i>Journal of Cellular and Molecular Medicine</i> , 2009, 13, 1653-1665.	3.6	38
51	Biodistribution of ¹⁰ B for Boron Neutron Capture Therapy (BNCT) in a Mouse Model after Injection of Sodium Mercaptoundecahydro-closo-dodecaborate and l-Boronophenylalanine. <i>Radiation Research</i> , 2009, 172, 493-499.	1.5	14
52	Uptake of two ¹⁰ B compounds in liver metastases of colorectal adenocarcinoma for extracorporeal irradiation with boron neutron capture therapy (EORTC Trial 11001). <i>International Journal of Cancer</i> , 2008, 122, 1164-1171.	5.1	63
53	Boron analysis and boron imaging in biological materials for Boron Neutron Capture Therapy (BNCT). <i>Critical Reviews in Oncology/Hematology</i> , 2008, 68, 66-90.	4.4	117
54	Laser postionization secondary neutral mass spectrometry in tissue: a powerful tool for elemental and molecular imaging in the development of targeted drugs. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 1763-1771.	4.1	28

#	ARTICLE	IF	CITATIONS
55	Preparation of cells cultured on silicon wafers for mass spectrometry analysis. <i>Microscopy Research and Technique</i> , 2005, 66, 248-258.	2.2	22
56	Neutron Activation of Patients Following Boron Neutron Capture Therapy of Brain Tumors at the High Flux Reactor (HFR) Petten (EORTC Trials 11961 and 11011). <i>Strahlentherapie Und Onkologie</i> , 2005, 181, 774-782.	2.0	17
57	Radiologic findings in patients treated with boron neutron capture therapy for glioblastoma multiforme within EORTC trial 11961. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 61, 392-399.	0.8	35
58	Stability of ¹⁰ B-l-boronophenylalanine- ⁶ fructose injection. <i>American Journal of Health-System Pharmacy</i> , 2005, 62, 2608-2610.	1.0	12
59	EELS Spectrum-Imaging for Boron Detection in Biological Cryofixed Tissues. <i>Instrumentation Science and Technology</i> , 2005, 33, 631-644.	1.8	7
60	Tissue uptake of BSH in patients with glioblastoma in the EORTC 11961 phase I BNCT trial. <i>Journal of Neuro-Oncology</i> , 2003, 62, 145-156.	2.9	52